Lungpacer Medical Inc. is developing a novel therapeutic solution for preserving or restoring the integrity and strength of the diaphragm muscle in critically ill patients who require mechanical ventilation. The proprietary Lungpacer system is designed to activate and exercise the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation catheter that is expected to save many lives, improve surviving patient outcomes and greatly reduce hospital care costs.
Intravenously inserted Lungpacer electrodes are designed to rhythmically activate the diaphragm. In critically ill patients who have failed or would typically fail to wean and become ventilator-dependent, the pacing therapy is expected to prevent or reverse diaphragm muscle-disuse atrophy and maintain diaphragmatic endurance, thus facilitating weaning of patients from MV. In addition, the paced diaphragm is expected to restore negative pressure ventilation, thereby potentially providing a more physiological respiratory pattern and reducing the levels of positive pressure ventilation and its harmful effects on the lungs.
These potentially beneficial effects of transvascular diaphragm pacing are expected to result in faster patient recovery, a shorter stay in intensive care, improved health outcomes and lower hospitalization costs.
CEO of Lungpacer Medical Inc., is a medical device executive with 30 years of industry and public company experience and an inventor/developer of dozens of medical products including the Angio-Seal Vascular Closure Device. Doug was formerly COO and board member of Kensey Nash Corporation (acquired in 2012 by Royal DSM for $360M). He has authored over 175 patents and managed the commercialization of multiple first of their kind products in cardiology, orthopedics, and general surgery.
Mike Favet, joined KCK as a Managing Director, Medical Technologies in 2016. Prior to joining KCK, he served in senior management positions for a variety of medical technology companies including Advanced Cardiac Therapeutics, Sonitus Medical, Ventus Medical, Boston Scientific and Guidant. KCK Group is a large, single family, evergreen fund that invests in multiple sectors including through a team focused on medical technology.
Joseph Kaufmann, is an Investment Manager at 4CGE LLC, a US based investment group. Joe also serves as the Chairman of the Board of privately held Essential Medical a startup medical device company specializing in large bore vascular closure products.
Former President and CEO of Kensey Nash Corporation (NASDAQ – KNSY) from 1995 to 2012 and CFO from 1989 to 1995. Kensey Nash was a leader in vascular closure, orthopedic/spine devices and resorbable biomaterial products. The company was sold to Royal DSM for $364 million in 2012.
Guillaume Darnand, is Investment Manager at Valiance, a London based investment firm. Guillaume is responsible for its portfolio of Life Sciences companies, investing growth capital into innovative medical technologies in Europe and in the US. Prior to that, Guillaume had a career in Investment Banking, advising large capitalization corporates on Mergers and Acquisitions and other corporate finance decisions including Capital Markets financing. Guillaume has experience in various sectors including Healthcare but also Consumer, Retail, Telecoms, e-Commerce, Oil & Gas. He graduated from ESSEC Business School in Paris.
Linda Clark, Vice President of Clinical Affairs, has more than 25 years of experience in critical care nursing and early stage start-up companies. She has managed and executed numerous clinical trials for novel devices from FIH to FDA completion and for CE mark approval. Her background includes trials in cardiology, cardiac surgery, neurosurgery and sleep apnea. Linda has held senior management positions for Abiomed Cardiovascular, Cardeon, Innercool, Paracor Medical, Respicardia and most recently LoneStar Heart.
Matt Gani, Vice President of Research, has over 25 years of experience leading medical product development projects involving electrical stimulation, pacemaker, and defibrillator devices. Matt previously served as the VP of Product Development for Northstar Neuroscience, a developer of cortical stimulation therapies, as the Senior Director for Biotronik, and as PM for Telectronics Pacing Systems, acquired by St. Jude Medical.
Viral Thakkar, Vice President of Operations, has more than 14 years of prior experience in managing and execution of all phases of Medical Device Design and Development from market definition through production and release. Viral has worked in medical device companies, internationally, in projects involving power-actuated surgical stapling devices, cardiovascular and peripheral stents, stent delivery systems, embolic protection devices, catheter based intra-vascular temperature management devices. Previously, Viral has served in leadership roles for ZOLL, Boston Scientific, Radiant Medical, SMTPL & Power Medical Interventions.
Rosemarie, CPA, MBA, Vice President of Finance, has twenty-five years of accounting and finance experience. Ms. Dhavale previously was the Vice President of Finance at Delta Dental of Minnesota and was Senior Director of Finance at Kensey Nash Corporation, a medical device company (acquired by Royal DSM). She has been actively involved in analyzing new technologies and businesses throughout her career and lead accounting and finance teams in FP&A, implementations of systems and strategic initiatives.
Judy Ways, PhD, Vice President of Regulatory Affairs, has over 25 years of regulatory experience across medical devices, biologics and drug products in the areas of neurology, psychiatry, immunology, gene therapy, and blood products. She has managed the regulatory activities for multiple medical devices in the US, Europe and other international markets and has a strong track record for worldwide approvals for first-in-kind devices. Judy has also built regulatory, compliance, and quality systems from the ground up for several start-up companies. She worked at and was on the founding team of medical device start-ups Neuronetics and Neuron Therapeutics. Earlier in her career, she worked at MedImmune, Aventis Behring (Centeon) and Glaxo. Judy obtained her PhD. in Immunology and Cancer Biology from Stanford University.